Clinical Results

Clinical Study Results for Moderate to Severe Rheumatoid Arthritis Patients Taking CIMZIA

When your rheumatoid arthritis (RA) is active, inflammation is occurring, causing joint pain and stiffness. Ongoing inflammation can also cause damage to your joints. Inflammation is caused by excess tumor necrosis factor (TNF), a protein produced by the immune system. CIMZIA is a prescription medication that is injected under the skin and targets TNF, providing noticeable relief from the joint pain and stiffness of moderate to severe RA.

Results varied from patient to patient, but in clinical trials with CIMZIA, many patients with moderate to severe rheumatoid arthritis experienced noticeable relief of their RA symptoms compared to patients taking a placebo.

  • Noticeable RA relief: In clinical trials, about six out of every 10 patients who received CIMZIA experienced noticeable RA symptom relief including improvement in pain, swelling, and tenderness.
  • The majority of patients noticed results within 24 weeks, with some patients reporting improvement in as fast as one to two weeks.
  • Stopped further joint damage for most patients as shown by their X-rays at both six months and one year in a clinical trial versus patients in a control group.
  • Improvement in common everyday activities: In clinical trials, patients on CIMZIA reported improvement in everyday activities such as showering, getting dressed, doing chores, walking short distances, and running simple errands.

The results from these clinical trials were based on patients who received the recommended starter and maintenance doses of CIMZIA.

Every patient is different and responds differently to therapy—so your results may vary. Talk to your doctor to see if CIMZIA may be right for you.

Clinical Study Results for Psoriatic Arthritis Patients Taking CIMZIA

When your psoriatic arthritis (PsA) is active, inflammation is occurring, which can cause joint pain, stiffness, and skin lesions. Ongoing inflammation can also cause damage to your joints. CIMZIA works by blocking the action of tumor necrosis factor (TNF), a protein produced by the immune system that causes inflammation. CIMZIA is a prescription medication that is injected under the skin and targets TNF, providing noticeable relief from the joint pain, stiffness, and skin symptoms of PsA.

Results vary from patient to patient, but in a clinical trial, the majority of patients taking CIMZIA with active psoriatic arthritis experienced noticeable relief of their PsA symptoms compared to patients taking a placebo.

  • Noticeable PsA relief: In a clinical trial, most people who took CIMZIA experienced relief from the joint pain and tenderness of PsA within 12 weeks and some in as fast as one to two weeks after their first dose versus placebo.
    • Skin improvement: The majority of patients who had active skin involvement reported 75% skin improvement by 24 weeks.
  • Improvement in everyday activities: In the same clinical trial, CIMZIA made it easier to perform many common daily activities, such as running errands, getting dressed, and getting in and out of a car.

The results from the clinical trial were based on patients who received the recommended starter and maintenance doses of CIMZIA.

Every patient is different and responds differently to therapy—so your results may vary. Talk to your doctor to see if CIMZIA may be right for you.

Clinical Study Results for Ankylosing Spondylitis Patients Taking CIMZIA

When your ankylosing spondylitis (AS) is active, inflammation is occurring, which may cause damage to the joints of the spine and, in some patients, other parts of the body. While the root cause of AS is unknown, too much of a protein called tumor necrosis factor (TNF) can contribute to the inflammation that occurs. CIMZIA works by blocking the action of TNF.

Results vary from patient to patient, but in a clinical trial with CIMZIA, the majority of patients with active ankylosing spondylitis experienced relief of their AS symptoms compared to patients taking a placebo.

  • Noticeable AS relief: In a clinical trial, CIMZIA was proven versus placebo to provide noticeable AS symptom relief, including improvements in morning stiffness, tenderness, and inflammatory back pain, for the majority of patients after 12 weeks and for some in as fast as one to two weeks.
  • Reduced AS disease activity: In the same clinical trial, CIMZIA reduced AS disease activity after 12 weeks, including improvements in pain, stiffness, tenderness, and fatigue, versus placebo.
  • Improvement in common activities: In the same clinical trial, patients on CIMZIA after 12 weeks reported improvement in doing certain common activities, such as looking over the shoulder without turning the body, putting on socks without help, bending from the waist to pick up a pen from the floor without help, or gardening.

The clinical study results above were based on patients who received the recommended starter and maintenance doses of CIMZIA.

Every patient is different and responds differently to therapy—so your results may vary. Talk to your doctor to see if CIMZIA may be right for you.

Clinical Study Results for Crohn’s Disease Patients Taking CIMZIA

When your moderate to severe Crohn’s disease (CD) is active, inflammation occurs in the digestive tract, causing symptoms such as diarrhea and stomach pain. CIMZIA works by blocking the action of tumor necrosis factor (TNF), a protein produced by the immune system that causes inflammation. CIMZIA may be right for you when other conventional treatments have not worked.

In a clinical trial, CIMZIA was proven versus placebo to provide noticeable symptom relief for the majority of patients who continued to take CIMZIA for 26 weeks of treatment versus placebo. In another clinical trial, some patients experienced noticeable symptom relief in as fast as six weeks.

The clinical study results above were based on patients who received the recommended starter and maintenance doses of CIMZIA.

Every patient is different and responds differently to therapy—so your results may vary. Talk to your doctor to see if CIMZIA may be right for you.

Important Safety Information you should know about CIMZIA® (certolizumab pegol)

What is the most important information I should know about CIMZIA?

CIMZIA may cause serious side effects, including:

CIMZIA is a prescription medicine called a Tumor Necrosis Factor (TNF) blocker that can lower the ability of your immune system to fight infections. Some people who received CIMZIA have developed serious infections, including tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some of these serious infections have caused hospitalization and death.

  • Your healthcare provider should test you for TB before starting CIMZIA.
  • Your healthcare provider should monitor you closely for signs and symptoms of TB during treatment with CIMZIA.

Before starting CIMZIA, tell your healthcare provider if you:

  • think you have an infection or have symptoms of an infection such as:
    • fever, sweat, or chills
    • muscle aches
    • cough
    • shortness of breath
    • blood in phlegm
    • weight loss
    • warm, red, or painful skin or sores on your body
    • diarrhea or stomach pain
    • burning when you urinate or urinate more often than normal
    • feeling very tired
  • are being treated for an infection
  • get a lot of infections or have infections that keep coming back
  • have diabetes, HIV-1 or a weak immune system. People with these conditions have a higher chance for infections.
  • have tuberculosis (TB), or have been in close contact with someone with TB
  • were born in, live, have lived, or traveled to certain countries where there is more risk for getting TB. Ask your healthcare provider if you are not sure.
  • live, have lived, or traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased risk for getting certain kinds of fungal infections (histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis). These infections may develop or become more severe if you receive CIMZIA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common.
  • have or have had hepatitis B
  • use the medicine Kineret® (anakinra), Orencia® (abatacept), Rituxan® (rituximab), or Tysabri® (natalizumab)

Stop using CIMZIA, and tell your healthcare provider right away if you have any of the symptoms of an infection listed above.

Cancer.

  • For people who receive TNF blockers, including CIMZIA, the chances of getting certain types of cancers may increase.
  • Some children, teenagers, and young adults who received TNF blockers, including CIMZIA, have developed lymphoma and other certain types of rare cancers, some of which have caused death. These cancers are not usually seen in this age group. CIMZIA is not for use in children.
  • People with inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, especially those with very active disease, may be more likely to get lymphoma.
  • Some people who receive TNF blockers, including CIMZIA, have developed a rare type of cancer which may cause death, called hepatosplenic T-cell lymphoma. Most of these people were male teenagers and young adult males with Crohn's disease or ulcerative colitis. Also, most of these people had been treated with both a TNF blocker and another medicine called IMURAN® (azathioprine) or PURINETHOL® (6-mercaptopurine, 6-MP).
  • Some people who receive CIMZIA have developed certain types of skin cancer. Tell your healthcare provider if you develop any changes in the appearance of your skin, including growths on your skin, during or after treatment with CIMZIA. You should see your healthcare provider periodically during treatment for skin examinations, especially if you have a history of skin cancer.

What is CIMZIA?

CIMZIA is a prescription medicine called a Tumor Necrosis Factor (TNF) blocker used in adults to:

  • Lessen the signs and symptoms of moderately to severely active Crohn’s disease (CD) in adults who have not been helped enough by usual treatments
  • Treat moderately to severely active rheumatoid arthritis (RA)
  • Treat active psoriatic arthritis (PsA)
  • Treat active ankylosing spondylitis (AS)
  • Treat moderate to severe plaque psoriasis (PsO) in adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills)

It is not known if CIMZIA is safe and effective in children.

Before receiving CIMZIA, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection
  • have or have had lymphoma or any other type of cancer
  • have or had congestive heart failure
  • have or have had seizures, any numbness or tingling, or a disease that affects your nervous system such as multiple sclerosis or Guillain-Barre syndrome.
  • are scheduled to receive a vaccine. Do not receive a live vaccine while receiving CIMZIA.
  • are allergic to certolizumab pegol or any of the ingredients in CIMZIA. See the Medication Guide for a complete list of the ingredients in CIMZIA.
  • are allergic to rubber or latex; 7% of the plastic needle shield inside the removable cap is derived from natural rubber latex.
  • are pregnant or plan to become pregnant. Tell your healthcare provider right away if you become pregnant during treatment with CIMZIA.

Pregnancy Registry: If you become pregnant during treatment with CIMZIA, talk to your healthcare provider about registering in the pregnancy exposure registry for CIMZIA. You can enroll in this registry by calling 1-877-311-8972. The purpose of this registry is to collect information about the safety of CIMZIA during pregnancy.

  • are breastfeeding or plan to breastfeed. Talk to your healthcare provider about the best way to feed your baby during treatment with CIMZIA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.

How will I receive CIMZIA?

CIMZIA comes as a lyophilized powder or a solution in a prefilled syringe for injection. If your healthcare provider prescribes the CIMZIA powder, CIMZIA should be injected by a healthcare provider. If your healthcare provider prescribes the prefilled syringe, you will be trained on how to inject CIMZIA. See the booklet called “Instructions for Use” packaged in your CIMZIA prefilled syringe kit on how to inject CIMZIA the right way. Do not give yourself an injection of CIMZIA unless you have been shown by your healthcare provider, or they can train someone you know to help you with your injection. CIMZIA is given by an injection under the skin. Your healthcare provider will tell you how much and how often to inject CIMZIA. Do not use more CIMZIA or inject more often than prescribed.

What are the possible side effects of CIMZIA?

CIMZIA can cause serious side effects, including:

  • See “What is the most important information I should know about CIMZIA?”
  • Heart failure including new heart failure or worsening of heart failure you already have. Symptoms include shortness of breath, swelling of your ankles or feet, or sudden weight gain.
  • Allergic reactions. Signs of an allergic reaction include a skin rash; swelling or itching of the face, tongue, lips, or throat; or trouble breathing.
  • Hepatitis B virus reactivation in people who carry the virus in their blood. In some cases, people who received CIMZIA have died because of the hepatitis B virus being reactivated. Your healthcare provider should monitor you carefully before and during treatment with CIMZIA to see if you carry the hepatitis B virus in your blood. Tell your healthcare provider if you have any of the following symptoms:
    • feel unwell
    • skin or eyes look yellow
    • tiredness (fatigue)
    • poor appetite or vomiting
    • pain on the right side of your stomach (abdomen)
  • New or worsening nervous system problems, such as multiple sclerosis (MS), Guillain-Barre syndrome, seizures, or inflammation of the nerves of the eyes. Symptoms may include:
    • dizziness
    • numbness or tingling
    • problems with your vision
    • weakness in your arms or legs
  • Blood problems. Your body may not make enough of the blood cells that help fight infections or help stop bleeding. Symptoms include a fever that does not go away, bruising or bleeding very easily, or looking very pale.
  • Immune reactions including a lupus-like syndrome. Symptoms include shortness of breath, joint pain, or a rash on your cheeks or arms that worsens with sun exposure.

Call your healthcare provider right away if you have any serious side effects listed above.

The most common side effects of CIMZIA include upper respiratory infections (flu, cold), rash, and urinary tract infections (bladder infections).

These are not all of the possible side effects of CIMZIA. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see the Medication Guide for CIMZIA and discuss it with your healthcare provider.